°Ç¸ç³Ô¹Ï

Skip to main content
Independent report

ACMD review of the evidence on the use and harms of etomidate

The report presents a review of etomidate and structurally related compounds and subsequent recommendations regarding their classification and scheduling.

From:
Advisory Council on the Misuse of Drugs
Published:
21 October 2025
Last updated:
6 February 2026 — See all updates

Documents

Cover letter: ACMD review of the evidence on the use and harms of etomidate

HTML

ACMD review of the evidence on the use and harms of etomidate (accessible)

HTML

PDF, 425 KB, 34 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

The government's response to the ACMD review of the evidence on the use and harms of etomidate (accessible)

HTML

PDF, 208 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Advisory Council on the Misuse of Drugs (ACMD) undertook a self-commissioned review to evaluate the potential harms associated with etomidate and related compounds. The review determined these substances may pose a risk to public health in the UK and considered their suitability for control under the Misuse of Drugs Act 1971.

Updates to this page

Published 21 October 2025
Last updated 6 February 2026 Show all updates

  1. Report updated with corrected chemical structures (methoxycarbonyl-etomidate and 2,6-diCl-3F-etomidate).

  2. Added the government's response to the ACMD review of the evidence on the use and harms of etomidate.

  3. First published.

Sign up for emails or print this page